These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 17601444

  • 1. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification.
    Bucci FA, Waterbury LD, Amico LM.
    Am J Ophthalmol; 2007 Jul; 144(1):146-7. PubMed ID: 17601444
    [Abstract] [Full Text] [Related]

  • 2. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
    Walters T, Raizman M, Ernest P, Gayton J, Lehmann R.
    J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.
    Bucci FA, Waterbury LD.
    Adv Ther; 2011 Dec; 28(12):1089-95. PubMed ID: 22105509
    [Abstract] [Full Text] [Related]

  • 6. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.
    Heier JS, Awh CC, Busbee BG, Waterbury LD, Daniel P, Stoller GL, Cleary TS.
    Retina; 2009 Oct; 29(9):1310-3. PubMed ID: 19934822
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
    Bucci FA, Waterbury LD.
    J Cataract Refract Surg; 2008 Aug; 34(8):1226; author reply 1226-7. PubMed ID: 18655957
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
    Bucci FA, Waterbury LD.
    Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702
    [Abstract] [Full Text] [Related]

  • 14. Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK).
    Durrie DS, Kennard MG, Boghossian AJ.
    Adv Ther; 2007 Jun; 24(6):1278-85. PubMed ID: 18165210
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification.
    Sahu S, Ram J, Bansal R, Pandav SS, Gupta A.
    J Cataract Refract Surg; 2015 Oct; 41(10):2043-8. PubMed ID: 26703278
    [Abstract] [Full Text] [Related]

  • 19. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%.
    Schoenberger SD, Kim SJ, Sheng J, Calcutt MW.
    JAMA Ophthalmol; 2014 Feb; 132(2):150-4. PubMed ID: 24264034
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.